| 0.03165 0 (0%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.26 | 1-year : | 1.57 |
| Resists | First : | 1.08 | Second : | 1.35 |
| Pivot price | 0.91 |
|||
| Supports | First : | 0.64 | Second : | 0.54 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.98 |
| MA(100) : | 1.49 |
MA(250) : | 2.27 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.2 | D(3) : | 20 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 7.19 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADXS ] has closed above bottom band by 16.8%. Bollinger Bands are 24.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.85 - 0.86 | 0.86 - 0.86 |
| Low: | 0.68 - 0.69 | 0.69 - 0.69 |
| Close: | 0.71 - 0.72 | 0.72 - 0.73 |
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Thu, 19 Jan 2023
Advaxis and Ayala Pharmaceuticals Complete Merger - GlobeNewswire
Thu, 20 Oct 2022
Advaxis enters merger deal with biotech firm Ayala - Pharmaceutical Technology
Wed, 19 Oct 2022
Advaxis and Ayala Pharmaceuticals To Merge - citybiz
Wed, 19 Oct 2022
Advaxis spies merger with Ayala as route back to Nasdaq - Fierce Biotech
Fri, 17 Dec 2021
Advaxis wins shareholder approval for Biosight merger (NASDAQ:ADXS) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 1.49e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.734e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 419.5 % |
| Return on Equity (ttm) | -95.9 % |
| Qtrly Rev. Growth | 692000 % |
| Gross Profit (p.s.) | -42.92 |
| Sales Per Share | -81.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 39890 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2019-03-28 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|